Association Between Self-Monitored Blood Glucose and Continuous Glucose Monitoring in Youth With Type 1 Diabetes and Medicaid Insurance
- 14 February 2025
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (4) , 632-638
Abstract
OBJECTIVE: Youth with type 1 diabetes (T1D) and Medicaid must demonstrate they have self-monitored their blood glucose level at least four times daily to receive continuous glucose monitors (CGMs). New California Medicaid policies eliminated this requirement and, thus, CGM access has increased. This study examines whether infrequent baseline self-monitored blood glucose (SMBG) checks result in suboptimal outcomes or nonadherence with CGM use. RESEARCH DESIGN AND METHODS: This retrospective study included youth with T1D and Medicaid who started CGM after January 2019, when newer models no longer needed calibration, at two large health care systems. Patients were stratified by data on baseline SMBG frequency (<4 vs. ≥4 checks daily) collected at the clinic visit prior to starting CGM. Differences between SMBG groups in CGM adherence and HbA1c over time were assessed by a mixed-effects linear regression model and fixed-effect interaction term. Patients were surveyed to explore individual impact of CGM on diabetes management. RESULTS: We followed 78 youth for 6 months. CGM adherence was similar between SMBG frequency groups at 3 months (68.7% vs. 68.4%; P = 0.97) and sustained at 6 months. HbA1c values improved in both groups at 3 months, with a larger improvement in those with SMBG <4 daily checks (1.3% vs. 0.4%), and sustained at 6 months. Patient surveys (n = 35) reported high engagement with CGM and increased insulin boluses after initiation. CONCLUSIONS: Patients using CGM demonstrated improvement in HbA1c regardless of prior SMBG. Increased engagement with CGM likely promoted increased insulin boluses. Therefore, restriction of CGM to those with SMBG ≥4 daily checks is an unnecessary barrier, excluding those who could potentially benefit the most.Keywords
Funding Information
- CDI Fellows Research Support Award for 2022 (CDI-FRSA-07012022)
- National Center for Advancing Translational Sciences UCLA CTSI Grant (UL1TR001881)
This publication has 24 references indexed in Scilit:
- Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement CollaborativeDiabetes Technology & Therapeutics, 2023
- A systematic review: Cost‐effectiveness of continuous glucose monitoring compared to self‐monitoring of blood glucose in type 1 diabetesEndocrinology, Diabetes & Metabolism, 2022
- Solutions to Address Inequity in Diabetes Technology Use in Type 1 Diabetes: Results from Multidisciplinary Stakeholder Co-creation WorkshopsDiabetes Technology & Therapeutics, 2022
- Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark StudyDiabetes Technology & Therapeutics, 2021
- HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the Influence of Technology and Socioeconomic Status on HbA1c in the T1D Exchange Clinic Registry FindingsDiabetes Technology & Therapeutics, 2020
- Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and UnjustifiedDiabetes Technology & Therapeutics, 2020
- Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 DiabetesDiabetes Technology & Therapeutics, 2019
- Sustained Continuous Glucose Monitor Use in Low-Income Youth with Type 1 Diabetes Following Insurance Coverage Supports Expansion of Continuous Glucose Monitor Coverage for AllDiabetes Technology & Therapeutics, 2018
- Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic ControlDiabetes Technology & Therapeutics, 2018
- Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of LifeDiabetes Technology & Therapeutics, 2015